Amit Govil is a Nephrology physician affiliated with University of Cincinnati. OpenAlex indexes 73 publications with 1,875 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
231 Albert Sabin Way
Ml0585
Cincinnati, OH 452670585
Telephone
513-558-0668Registry record last updated 14 Aug 2017.
Clinical trials
- Veloxis de Novo Kidney Transplant ECSWD
Sponsor: Simon Tremblay, PharmD, PhD
- Quantitating the Impact of Plerixafor
Sponsor: E. Steve Woodle
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Mallinckrodt Hospital Products Inc.Program year202523 payments$29,476openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year202522 payments$16,518openpaymentsdata.cms.gov ↗
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.1%Beta blocker36.1%Carvedilol57%Metoprolol Tartrate43%Part D<11 patientsCalcium channel blocker34.9%Nifedipine Er100%Part D≥12 patientsAnti-infectives
15.7%Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor15.7%Valganciclovir Hcl100%Part D<11 patientsMetabolism & gastrointestinal
13.3%Proton pump inhibitor13.3%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Antibody-mediated Rejection in Kidney Transplant: An Unmastered Area
Indian Journal of Transplantation
2024 - Viral specific T cell therapy in kidney transplant recipients – A single‐center experience
Transplant Infectious Disease
2023 - Presence of Panel-reactive Antibodies after Penetrating Keratoplasty
Ocular Immunology and Inflammation
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Alberto Espay, MD
University of Cincinnati
Henry Nasrallah, MD
University of Cincinnati
Elyse Lower, MD
University of Cincinnati
Ahmad Sedaghat, MD, PhD
University of Cincinnati
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”